- Home
- IMSR vs ZURA Comparison
IMSR vs ZURA Comparison
Compare IMSR & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMSR | ZURA |
|---|---|---|
| Founded | 2013 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 435.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IMSR | ZURA |
|---|---|---|
| Price | $6.42 | $6.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.78 |
| AVG Volume (30 Days) | ★ 1.2M | 457.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.95 | $0.99 |
| 52 Week High | $16.38 | $7.25 |
Technical Indicators
Market Signals| Indicator | IMSR | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 45.86 |
| Support Level | $5.98 | $5.62 |
| Resistance Level | $7.59 | $6.90 |
| Average True Range (ATR) | 0.57 | 0.52 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 26.11 | 0.98 |
Price Performance
Historical ComparisonAbout IMSR Terrestrial Energy Inc.
Terrestrial Energy Inc is an industry-leading technology company committed to delivering reliable, emission-free, and cost-competitive nuclear energy with a transformative advanced reactor, the Integral Molten Salt Reactor (IMSR). Its mission is to transform global energy markets by commercializing its IMSR Plant, which will deliver low-carbon electricity and industrial heat with superior economics, speed to deployment, and siting flexibility.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.